Encouraging effect of tocilizumab and remdesivir in treatment of COVID-19

Abstract

Novel corona 2019 further named, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the outbreak has started from Wuhan city of china in December 2019 and within short spam, its spread in almost 200 countries, and hence world health organization declared it a pandemic emergency. At present no licensed therapy presents or vaccine or effective agents available in the management of COVID-19. The severity of this virus can be categorized into three phases initial mild symptomatic phase, respiratory infection phase, and Cytokinine storm phase. The initial mild symptomatic phase can be identified by a cough, fever, severe diarrhea, tastelessness, etc. In some clinical trials, these symptoms are treated with traditional therapy such as azithromycin, lopinavir, etc. But if not treated, it leads to pneumonia, responsible for the shortening of breathing but apart from this currently available data has shown a correlation between proinflammatory factors like interleukin and COVID 19 infections. Tocilizumab, USFDA approved in the treatment of Chimeric antigen receptors T cell therapy and now shown effectiveness in COVID-19 especially against cytokine release syndrome and lowered the mortality rate, however outcome of ongoing clinical trials will prove its confirmatory treatment against COVID-19. For such severe pandemic disease, other promising agents like Remdesivir or Tocilizumab that's giving a really high recovery rate with reduced mortality rates in severe condition of COVID-19. Because of the severity and mortality rate from COVID-19, the globe needs promising, efficient treatment, sharing early discharge of patients, and reduced mortality which can be expected from Tocilizumab or Remdesivir in near future.